{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:16Z","timestamp":1786980076471,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00392-020-01648-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T07:03:08Z","timestamp":1586934188000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis"],"prefix":"10.1007","volume":"110","author":[{"given":"Shira","family":"Peleg Hasson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Salwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Sivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Shamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Shmilovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Moshkovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"livia","family":"Kapusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"Rozenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Laufer-Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"1648_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116\u2013129","journal-title":"Eur J Cancer"},{"key":"1648_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310","journal-title":"Immunity"},{"key":"1648_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"10","key":"1648_CR4","first-page":"2117","volume":"6","author":"AR Jazirehi","year":"2016","unstructured":"Jazirehi AR, Lim A, Dinh T (2016) PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res 6(10):2117\u20132128","journal-title":"Am J Cancer Res"},{"key":"1648_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"1648_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S et al (2017) Checkpoint inhibitors in metastatic egfr-mutated non-small cell lung cancer: a meta-analysis. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.007","journal-title":"J Thorac Oncol"},{"key":"1648_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, De Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:447\u2013458","journal-title":"Lancet Oncol"},{"key":"1648_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.009","author":"CW Guo","year":"2020","unstructured":"Guo CW, Alexander M, Dib Y et al (2020) A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.009","journal-title":"Eur J Cancer"},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"key":"1648_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1716078","journal-title":"N Engl J Med"},{"key":"1648_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, De Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"key":"1648_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"1648_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"1648_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"Mir H, Alhussein M, Alrashidi S et al (2018) Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol 34:1059\u20131068","journal-title":"Can J Cardiol"},{"key":"1648_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"1648_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933","journal-title":"Lancet"},{"key":"1648_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht210","author":"ALP Caforio","year":"2013","unstructured":"Caforio ALP, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/eht210","journal-title":"Eur Heart J"},{"key":"1648_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.07.025","author":"R Pradhan","year":"2019","unstructured":"Pradhan R, Nautiyal A, Singh S (2019) Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review. Int J Cardiol. https:\/\/doi.org\/10.1016\/j.ijcard.2019.07.025","journal-title":"Int J Cardiol"},{"key":"1648_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01577-w","author":"A Porcari","year":"2019","unstructured":"Porcari A, Merlo M, Crosera L et al (2019) Strain analysis reveals subtle systolic dysfunction in confirmed and suspected myocarditis with normal LVEF: a cardiac magnetic resonance study. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-019-01577-w","journal-title":"Clin Res Cardiol"},{"key":"1648_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","volume":"21","author":"L Zhang","year":"2019","unstructured":"Zhang L, Jones-O\u2019Connor M, Awadalla M et al (2019) Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Treat Opt Cardiovasc Med 21:32","journal-title":"Curr Treat Opt Cardiovasc Med"},{"key":"1648_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"1648_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"1648_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00392-019-01434-w","volume":"108","author":"M B\u00e4uml","year":"2019","unstructured":"B\u00e4uml M, Udi J, Klingel K et al (2019) Severe eosinophilic myocarditis associated with modafinil in a patient with normal peripheral eosinophil count. Clin Res Cardiol 108:963\u2013966","journal-title":"Clin Res Cardiol"},{"key":"1648_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-016-0152-y","journal-title":"J Immunother Cancer"},{"key":"1648_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jep194","author":"H Dalen","year":"2010","unstructured":"Dalen H, Thorstensen A, Aase SA et al (2010) Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr. https:\/\/doi.org\/10.1093\/ejechocard\/jep194","journal-title":"Eur J Echocardiogr"},{"key":"1648_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ et al (2019) Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115:854\u2013868","journal-title":"Cardiovasc Res"},{"key":"1648_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"1648_CR29","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G et al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2:e000247","journal-title":"ESMO Open"},{"key":"1648_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"1648_CR31","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/J.JACC.2016.09.937","volume":"68","author":"S Heymans","year":"2016","unstructured":"Heymans S, Eriksson U, Lehtonen J, Cooper LT (2016) The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol 68:2348\u20132364. https:\/\/doi.org\/10.1016\/J.JACC.2016.09.937","journal-title":"J Am Coll Cardiol"},{"key":"1648_CR32","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085\u20132087","journal-title":"Circulation"},{"key":"1648_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.163","author":"SC Smith","year":"1997","unstructured":"Smith SC, Ladenson JH, Mason JW, Jaffe AS (1997) Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. Circulation. https:\/\/doi.org\/10.1161\/01.CIR.95.1.163","journal-title":"Circulation"},{"key":"1648_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475\u20131487","journal-title":"J Am Coll Cardiol"},{"key":"1648_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-017-1109-3","author":"M Imbriaco","year":"2019","unstructured":"Imbriaco M, Nappi C, Puglia M et al (2019) Assessment of acute myocarditis by cardiac magnetic resonance imaging: comparison of qualitative and quantitative analysis methods. J Nucl Cardiol. https:\/\/doi.org\/10.1007\/s12350-017-1109-3","journal-title":"J Nucl Cardiol"},{"key":"1648_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.049","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD et al (2020) Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.049","journal-title":"J Am Coll Cardiol"},{"key":"1648_CR37","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","volume":"112","author":"MY Desai","year":"2018","unstructured":"Desai MY, Jellis CL, Kotecha R et al (2018) Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging 112:1132\u20131149","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01648-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T04:13:29Z","timestamp":1618460009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01648-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"15 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}